SP-003

SP-003 is a small molecule drug candidate developed by Sunny Pharmtech, currently in the research and development (R&D) stage for the treatment of folliculitis. It is formulated as an oral softgel capsule and is classified as a high-potency pharmaceutical, specifically categorized under Occupational Exposure Band 3 (OEB 3). Sunny Pharmtech, acting as a Contract Development and Manufacturing Organization (CDMO) and generic developer, focuses on complex formulations and high-potency active pharmaceutical ingredients (APIs); as such, SP-003 likely represents a specialized or generic version of an existing therapeutic agent used to treat inflammatory or infectious skin conditions. No specific molecular target or mechanism of action has been publicly disclosed for this pipeline candidate.